Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPR gene editing therapy for the treatment of ...

Strategic focus on developing NTLA-2002 and nex-z, which are expected to create significant near-term value, highlighting the company’s commitment to addressing unmet medical needs in hereditary ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

Intellia is developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema (HAE). In the past year, shares of Intellia have plunged 57.3% compared with the industry ...

Ronald Palacios Castrillo ¿Las terapias de edición genética realmente ayudan a los pacientes? Aunque ha habido un considerable entusiasmo sobre la perspectiva de administrar directamente una terapia d ...